These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 21157888)
1. Iron in sickle-cell disease: what have we learned over the years? Inati A; Khoriaty E; Musallam KM Pediatr Blood Cancer; 2011 Feb; 56(2):182-90. PubMed ID: 21157888 [TBL] [Abstract][Full Text] [Related]
2. Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease. Inati A; Musallam KM; Wood JC; Sheikh-Taha M; Daou L; Taher AT Eur J Haematol; 2009 Dec; 83(6):565-71. PubMed ID: 19737308 [TBL] [Abstract][Full Text] [Related]
3. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients. Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137 [TBL] [Abstract][Full Text] [Related]
4. Pathophysiology of transfusional iron overload: contrasting patterns in thalassemia major and sickle cell disease. Porter JB Hemoglobin; 2009; 33 Suppl 1():S37-45. PubMed ID: 20001631 [TBL] [Abstract][Full Text] [Related]
5. Approaches to transfusion therapy and iron overload in patients with sickle cell disease: results of an international survey. Vichinsky EP; Ohene-Frempong K; Pediatr Hematol Oncol; 2011 Feb; 28(1):37-42. PubMed ID: 20673029 [TBL] [Abstract][Full Text] [Related]
6. Microarray analysis of liver gene expression in iron overloaded patients with sickle cell anemia and beta-thalassemia. Flanagan JM; Steward S; Hankins JS; Howard TM; Neale G; Ware RE Am J Hematol; 2009 Jun; 84(6):328-34. PubMed ID: 19384939 [TBL] [Abstract][Full Text] [Related]
7. Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload. Fung EB; Harmatz P; Milet M; Ballas SK; De Castro L; Hagar W; Owen W; Olivieri N; Smith-Whitley K; Darbari D; Wang W; Vichinsky E; Am J Hematol; 2007 Apr; 82(4):255-65. PubMed ID: 17094096 [TBL] [Abstract][Full Text] [Related]
8. Transfusional iron burden and liver toxicity after bone marrow transplantation for acute myelogenous leukemia and hemoglobinopathies. Jastaniah W; Harmatz P; Pakbaz Z; Fischer R; Vichinsky E; Walters MC Pediatr Blood Cancer; 2008 Feb; 50(2):319-24. PubMed ID: 17557314 [TBL] [Abstract][Full Text] [Related]
9. The pathophysiology of transfusional iron overload. Porter JB; Garbowski M Hematol Oncol Clin North Am; 2014 Aug; 28(4):683-701, vi. PubMed ID: 25064708 [TBL] [Abstract][Full Text] [Related]
10. Chronic transfusions in patients with sickle cell disease. Indications and problems. Piomelli S Am J Pediatr Hematol Oncol; 1985; 7(1):51-5. PubMed ID: 4037243 [TBL] [Abstract][Full Text] [Related]
11. Concepts and goals in the management of transfusional iron overload. Porter JB Am J Hematol; 2007 Dec; 82(12 Suppl):1136-9. PubMed ID: 17968973 [TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease. Voskaridou E; Douskou M; Terpos E; Papassotiriou I; Stamoulakatou A; Ourailidis A; Loutradi A; Loukopoulos D Br J Haematol; 2004 Sep; 126(5):736-42. PubMed ID: 15327528 [TBL] [Abstract][Full Text] [Related]
13. Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Fung EB; Harmatz PR; Lee PD; Milet M; Bellevue R; Jeng MR; Kalinyak KA; Hudes M; Bhatia S; Vichinsky EP; Br J Haematol; 2006 Nov; 135(4):574-82. PubMed ID: 17054676 [TBL] [Abstract][Full Text] [Related]
14. No evidence for myocardial iron overload and free iron species in multitransfused patients with sickle/beta-thalassaemia. Ghoti H; Goitein O; Koren A; Levin C; Kushnir T; Rachmilewitz E; Konen E Eur J Haematol; 2010 Jan; 84(1):59-63. PubMed ID: 19793250 [TBL] [Abstract][Full Text] [Related]
15. Current issues in blood transfusion for sickle cell disease. Wahl S; Quirolo KC Curr Opin Pediatr; 2009 Feb; 21(1):15-21. PubMed ID: 19242238 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease. Kalpatthi R; Peters B; Kane I; Holloman D; Rackoff E; Disco D; Jackson S; Laver JH; Abboud MR Pediatr Blood Cancer; 2010 Dec; 55(7):1338-42. PubMed ID: 20981690 [TBL] [Abstract][Full Text] [Related]
17. Assessment of cardiac iron deposition in sickle cell disease using 3.0 Tesla cardiovascular magnetic resonance. Ibrahim el-SH; Rana FN; Johnson KR; White RD Hemoglobin; 2012; 36(4):343-61. PubMed ID: 22563880 [TBL] [Abstract][Full Text] [Related]
18. Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies. Taher A; Hershko C; Cappellini MD Br J Haematol; 2009 Dec; 147(5):634-40. PubMed ID: 19681884 [TBL] [Abstract][Full Text] [Related]
20. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]